TSXV:CZO - Post Discussion
Post by
prophetoffactz on Feb 22, 2024 1:30pm
New 52-week high for S&P Biotech ETF
The stars are aligning if this merger closes as
the S&P Biotech is on the verge of a potential
multi-year breakout. This could happen as the daisy chain of events then hits the market with CZO on NASDAQ, potential analyst support, and fully financed
for its near-term revenue generating opportunities. With
a potential multi-year breakout in biotech there could be
renwed interest in AEZS's early-stage pipeline. AEZS's
pipeline targets multi-billion dollar market opportunities.
The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business, which is optimally positioned to deliver value as the biopharma sector recovers from its current levels." news release
$94.78
Be the first to comment on this post